Full Text View
Tabular View
No Study Results Posted
Related Studies
Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma (LAM-RFA)
This study is currently recruiting participants.
Study NCT00555334   Information provided by Sun Yat-sen University
First Received: November 7, 2007   Last Updated: March 31, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatocellular Carcinoma
Liver Cancer
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Hepatocellular
Liver Neoplasms
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
RFA
lamivudine or entecavir
Additional drug interventions recognized in this trial
Entecavir
Lamivudine
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Sun Yat-sen University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services